Optimal dose finding with the BOIN-ET family

Why the optimal biological dose

For chemotherapy the most effective dose is usually taken to be the most toxic one that is still acceptable, the maximum tolerated dose (MTD). For targeted and immune therapies the response may level off, or even fall, below the MTD, and the aim is then the optimal biological dose (OBD), which weighs the response against the toxicity. The BOIN-ET design of Takeda, Taguri and Morita (2018) decides the next dose from both the DLT rate and the response rate at the current dose, and selects the OBD at the end of the trial.

The package provides four designs of this family:

The rules follow the R packages of the authors, ‘boinet’ (Yamaguchi, Takeda and Maruo, 2025) for the first two and ‘bfboinet’ for the third, with the changes described below, and the article for BOIN-ETC, with the rules of the code of the authors as options. The trials and the selection of the OBD run in C++.

The boundaries and the decision table

The DLT rate at the current dose is compared with two boundaries, lambda1 and lambda2, and the response rate with one, eta1. They minimize the probability of an incorrect decision, as found by the grid search of boinet::gridoptim().

bd <- boin_et_boundary(target = 0.30, target_resp = 0.60)
bd
#> BOIN-ET boundaries
#>   target DLT rate      : 0.3
#>   target response rate : 0.6
#>   p_saf / p_tox        : 0.03 / 0.42
#>   p_saf_resp           : 0.36
#> 
#>   lambda1 (escalate)   : 0.14
#>   lambda2 (de-escalate): 0.35
#>   eta1 (response)      : 0.48
#>   probability of an incorrect decision: 0.04703

With a target DLT rate of 0.30, a target response rate of 0.60 and the design parameters of Takeda et al. (2018), the boundaries are 0.14 for lambda1, 0.35 for lambda2 and 0.48 for eta1, the values of the article. The decision at the current dose is then

boin_et_decision_table(target = 0.30, target_resp = 0.60, n = c(3, 6))
#> BOIN-ET decision table
#>   lambda1 = 0.14, lambda2 = 0.35, eta1 = 0.48
#> 
#> 3 patients
#>     Responses
#> DLTs 0     1     2  3 
#>    0 E     E     S  S 
#>    1 E/S/D E/S/D S  S 
#>    2 D     D     D  D 
#>    3 D*    D*    D* D*
#> 
#> 6 patients
#>     Responses
#> DLTs 0     1     2     3  4  5  6 
#>    0 E     E     E     S  S  S  S 
#>    1 E/S/D E/S/D E/S/D S  S  S  S 
#>    2 E/S/D E/S/D E/S/D S  S  S  S 
#>    3 D     D     D     D  D  D  D 
#>    4 D*    D*    D*    D* D* D* D*
#>    5 D*    D*    D*    D* D* D* D*
#>    6 D*    D*    D*    D* D* D* D*
#> 
#> E = escalate, S = stay, D = de-escalate, E/S/D = choose among the current and neighboring doses;
#> * = the dose is no longer admissible

These are the decisions of Table 2 of Takeda et al. (2018). A star marks the counts that make a dose inadmissible: by default, as in ‘boinet’, a dose is excluded when the posterior probability that its DLT rate exceeds target is above cutoff_eli = 0.95, or when the posterior probability that its response rate is below p_saf_resp is above cutoff_eli_resp = 0.99. p_eli and p_eli_resp change the two rates; the simulations of the article exclude a dose when the posterior probability that its DLT rate is below 0.40 is less than 0.10, or that its response rate is above 0.20 is less than 0.10 (p_eli = 0.40, p_eli_resp = 0.20, cutoff_eli = 0.90 and cutoff_eli_resp = 0.90).

Operating characteristics for one scenario

Scenario 1 of Takeda et al. (2018) has six doses, twelve cohorts of three patients and a trial that starts at the lowest dose.

p_true <- c(0.05, 0.15, 0.25, 0.30, 0.35, 0.40)
p_resp <- c(0.05, 0.35, 0.55, 0.65, 0.75, 0.70)

oc <- sim_boin_et(target = 0.30, target_resp = 0.60, p_true = p_true,
                  p_resp = p_resp, n_cohort = 12, cohort_size = 3,
                  n_trials = 2000, seed = 123)
oc
#> BOIN-ET operating characteristics
#>   target DLT rate      : 0.3
#>   target response rate : 0.6
#>   trials               : 2000
#>   cohorts              : 12 of size 3
#>   max sample size      : 36
#>   lambda1 / lambda2    : 0.14 / 0.35
#>   eta1                 : 0.48
#>   OBD selection        : max_resp with observed response rates
#> 
#>                        DL1  DL2  DL3  DL4  DL5  DL6 Total / No OBD
#> True DLT rate (%)      5.0 15.0 25.0 30.0 35.0 40.0               
#> True response rate (%) 5.0 35.0 55.0 65.0 75.0 70.0               
#> OBD selected (%)       1.5 16.1 47.1 26.7  7.0  0.5            1.1
#> Patients treated       3.5  8.9 14.3  7.1  1.8  0.2           35.8
#> Patients with DLT      0.2  1.3  3.6  2.2  0.6  0.1            8.0
#> Patients with response 0.2  3.1  7.9  4.7  1.4  0.1           17.3
#> 
#> Trials stopped early: 1.1%

The output gives the percentage of trials selecting each dose as the OBD, the average numbers of patients, DLTs and responses at each dose, and the percentage of trials stopped early. Here dose 3 is selected most often, in 47 percent of the trials, and 1.1 percent of the trials select no OBD.

Several scenarios are run with sim_boin_et_multi(). In scenario 7 of the article the response rate peaks at dose 2 while the DLT rate goes on rising.

scenarios <- list(
  list(name = "Scenario 1", p_true = p_true, p_resp = p_resp),
  list(name = "Scenario 7", p_true = c(0.05, 0.15, 0.25, 0.35, 0.45, 0.55),
       p_resp = c(0.30, 0.70, 0.60, 0.50, 0.40, 0.30))
)
sim_boin_et_multi(target = 0.30, target_resp = 0.60, scenarios = scenarios,
                  n_cohort = 12, cohort_size = 3, n_trials = 1000,
                  seed = 123)
#> BOIN-ET operating characteristics across 2 scenarios
#>   target DLT rate      : 0.3
#>   target response rate : 0.6
#>   trials each          : 1000
#>   max sample size      : 36
#>   OBD selection        : max_resp with observed response rates
#> 
#>    Scenario                   Item  DL1  DL2  DL3  DL4  DL5  DL6 Total / No OBD
#>  Scenario 1      True DLT rate (%)  5.0 15.0 25.0 30.0 35.0 40.0               
#>             True response rate (%)  5.0 35.0 55.0 65.0 75.0 70.0               
#>                   OBD selected (%)  1.7 17.0 47.4 26.5  6.1  0.3            1.0
#>                   Patients treated  3.5  9.1 14.4  7.0  1.7  0.2           35.9
#>                  Patients with DLT  0.2  1.4  3.6  2.2  0.6  0.1            8.0
#>             Patients with response  0.2  3.1  7.9  4.6  1.2  0.1           17.3
#>  Scenario 7      True DLT rate (%)  5.0 15.0 25.0 35.0 45.0 55.0               
#>             True response rate (%) 30.0 70.0 60.0 50.0 40.0 30.0               
#>                   OBD selected (%)  3.0 80.8 12.1  3.3  0.7  0.0            0.1
#>                   Patients treated  5.6 25.5  3.4  1.1  0.4  0.1           36.0
#>                  Patients with DLT  0.3  3.9  0.8  0.4  0.1  0.1            5.6
#>             Patients with response  1.7 17.8  2.1  0.6  0.1  0.0           22.3

Selecting the OBD

At the end of a trial the DLT rates of the doses tried are made monotone by isotonic regression, and the response rates are estimated with one of three estimators (est_method): the observed rates (the default), the model-averaged unimodal isotonic regression of Lin and Yin (2017) ("multi_iso"), or the fractional polynomial logistic regression of Takeda et al. (2018) ("fp_logistic", which needs the ‘mfp’ package). The OBD is then chosen among the admissible doses with one of four rules (obd_method): the highest estimated response rate up to the estimated MTD ("max_resp", the default), or the highest value of one of the three utilities compared by Yamaguchi et al. (2024) ("utility_weighted", "utility_truncated_linear" and "utility_scoring").

boin_et_select_obd() selects the OBD from the final data of trials, so the same simulated trials can be judged under every rule.

oc_kept <- sim_boin_et(target = 0.30, target_resp = 0.60, p_true = p_true,
                       p_resp = p_resp, n_cohort = 12, cohort_size = 3,
                       n_trials = 2000, keep_trials = TRUE, seed = 123)
tr <- oc_kept$trials

select_percent <- function(est_method, obd_method) {
  obd <- boin_et_select_obd(n_pts = tr$n_pts, n_tox = tr$n_tox,
                            n_resp = tr$n_resp, target = 0.30,
                            target_resp = 0.60, est_method = est_method,
                            obd_method = obd_method,
                            early_stop = tr$early_stop)$obd
  as.numeric(table(factor(obd, levels = 1:6))) / length(obd) * 100
}

rules <- c("max_resp", "utility_weighted", "utility_truncated_linear",
           "utility_scoring")
selection <- rbind(
  t(sapply(rules, function(m) select_percent("observed", m))),
  "max_resp, multi_iso" = select_percent("multi_iso", "max_resp")
)
colnames(selection) <- paste0("DL", 1:6)
round(selection, 1)
#>                          DL1  DL2  DL3  DL4  DL5 DL6
#> max_resp                 1.5 16.1 47.1 26.7  7.0 0.5
#> utility_weighted         1.5 16.4 44.0 28.5  7.6 0.8
#> utility_truncated_linear 5.9 34.3 39.1 15.7  3.3 0.4
#> utility_scoring          2.1 16.6 39.4 29.8 10.1 1.0
#> max_resp, multi_iso      0.2 14.4 48.9 27.7  7.0 0.5

all.equal(unname(selection["max_resp", ]), unname(oc_kept$sel_percent))
#> [1] TRUE

The first row is the selection of sim_boin_et(), which calls boin_et_select_obd() with the same defaults. The fractional polynomial is fitted once for every distinct set of final data and takes longer:

sim_boin_et(target = 0.30, target_resp = 0.60, p_true = p_true,
            p_resp = p_resp, n_cohort = 12, cohort_size = 3,
            n_trials = 2000, est_method = "fp_logistic", seed = 123)

Dose moves that differ from ‘boinet’

After each cohort the admissibility of every dose is derived again from its data, and the trial stops early when no dose is admissible, or when the dose should be lowered and no admissible dose is found at or below the intended one. When the intended dose is not admissible, a stay or a de-escalation moves to the highest admissible dose below it, and an escalation to the lowest admissible dose above it, or stays when there is none.

Two rules differ from those of ‘boinet’ 1.6.0. Takeda et al. (2018) do not allow dose skipping during escalation, so a dose excluded by its DLT data also excludes every higher dose, as in the later BF-BOIN-ET design and the ‘bfboinet’ package, and an escalation from the highest dose ends the trial when that dose is excluded. In ‘boinet’, an escalation can skip a dose excluded by its DLT data and reach an untried higher dose, and an escalation from the highest dose stays there even when it is excluded. boinet_compatible = TRUE applies these rules of ‘boinet’ in every BOIN-ET and TITE-BOIN-ET function.

skip_design <- list(target = 0.30, target_resp = 0.60,
                    p_true = c(0.10, 0.20, 0.45, 0.50, 0.55),
                    p_resp = c(0.10, 0.20, 0.30, 0.50, 0.60),
                    n_cohort = 12, cohort_size = 3, n_trials = 2000,
                    seed = 123)
oc_default <- do.call(sim_boin_et, skip_design)
oc_boinet <- do.call(sim_boin_et,
                     c(skip_design, list(boinet_compatible = TRUE)))
round(rbind(default = oc_default$n_pts_dose,
            boinet = oc_boinet$n_pts_dose), 2)
#>          DL1   DL2  DL3  DL4  DL5
#> default 5.20 14.65 9.73 4.77 1.13
#> boinet  4.84 11.57 9.47 6.89 3.05

Doses 4 and 5, with DLT probabilities of 0.50 and 0.55, receive 5.9 patients per trial on average under the default rules and 9.9 under those of ‘boinet’, which let an escalation from dose 2 skip dose 3 once it is excluded.

TITE-BOIN-ET

When the DLT and the response take long to assess compared with the time between arrivals, TITE-BOIN-ET doses new patients while earlier ones are still assessed. A patient still under assessment counts in the DLT and response rates of a dose by the fraction of the window followed so far (Takeda et al., 2020), and the decision rule of BOIN-ET is applied to these rates. The admissibility of the doses counts such a patient as a patient without the event, as in ‘boinet’.

The first patient of a cohort arrives at the time of the previous decision, and the next decision is due when the next patient arrives. While fewer than a share min_completed_share of the patients at the current dose have finished both assessments, the decision waits for the next assessment to end. The default, 0.5, is the rule of boinet::tite.boinet(). The simulations of Takeda et al. (2020) did not wait (min_completed_share = 0), and the article recommends such a rule when the accrual is fast. By default the times to DLT and to response are Weibull, with late_fraction and resp_late_fraction of the events in the second half of each window, and they are linked by a Gaussian copula with correlation resp_cor.

The setting of Takeda et al. (2020) is a DLT window of 28 days, a response window of 56 days and one patient every 14 days; the unit of time is the day.

tite_design <- list(target = 0.30, target_resp = 0.60, p_true = p_true,
                    p_resp = p_resp, n_cohort = 12, cohort_size = 3,
                    window = 28, resp_window = 56, accrual_rate = 1 / 14,
                    n_trials = 1000, seed = 123)
oc_tite <- do.call(sim_tite_boin_et, tite_design)
oc_tite
#> TITE-BOIN-ET operating characteristics
#>   target DLT rate      : 0.3
#>   target response rate : 0.6
#>   trials               : 1000
#>   cohorts              : 12 of size 3
#>   max sample size      : 36
#>   lambda1 / lambda2    : 0.14 / 0.35
#>   eta1                 : 0.48
#>   OBD selection        : max_resp with observed response rates
#> 
#>                        DL1  DL2  DL3  DL4  DL5  DL6 Total / No OBD
#> True DLT rate (%)      5.0 15.0 25.0 30.0 35.0 40.0               
#> True response rate (%) 5.0 35.0 55.0 65.0 75.0 70.0               
#> OBD selected (%)       1.1 18.0 44.8 26.9  6.1  0.4            2.7
#> Patients treated       4.0  9.3 13.5  6.9  1.8  0.2           35.6
#> Patients with DLT      0.2  1.5  3.4  2.1  0.7  0.1            7.9
#> Patients with response 0.2  3.2  7.4  4.5  1.4  0.2           16.9
#> 
#> Trials stopped early: 2.7%
#> Average trial duration: 616.5

oc_tite_0 <- do.call(sim_tite_boin_et,
                     c(tite_design, list(min_completed_share = 0)))
round(rbind(
  "wait for half" = c(oc_tite$sel_percent, weeks = oc_tite$duration / 7),
  "no wait" = c(oc_tite_0$sel_percent, weeks = oc_tite_0$duration / 7)
), 1)
#>               DL1  DL2  DL3  DL4 DL5 DL6 weeks
#> wait for half 1.1 18.0 44.8 26.9 6.1 0.4  88.1
#> no wait       0.9 20.7 45.6 23.0 7.2 0.3  77.1

The trials last 88 weeks on average with the default rule and 77 weeks without waiting. The duration runs from the arrival of the first patient to the last decision, which is the end of both assessments of every patient when all cohorts are enrolled. The durations reported by Takeda et al. (2020) correspond to counting also the interval between arrivals before the first patient.

BF-BOIN-ET

In BF-BOIN-ET a cohort is treated at the current dose, and the next cohort starts with the first patient who arrives once the DLT outcomes of the cohort are known. The patients who arrive in between are backfilled one by one, when the current dose is not the lowest, to the lower dose with the highest utility among those with a promising response rate. The utility is defined by the scores psi00, psi_dlt_no_resp, psi_resp_no_dlt and psi11 of a patient without DLT or response, with a DLT only, with a response only and with both. The dose escalation uses the DLT rate at the current dose with the boundaries of BOIN, and stays after 1 DLT in 3 patients. A dose with n_elimination patients or more is excluded for good when its DLT or response data are poor, a dose excluded by its DLT data taking every higher dose with it. The OBD is the admissible dose up to the estimated MTD with the highest utility. The rules are those of bfboinet::get.oc.backboinet().

The example of ‘bfboinet’ has five doses, ten cohorts of three, windows of one month and three patients a month; the unit of time is the month.

bf_design <- list(target = 0.30, target_resp = 0.25,
                  p_true = c(0.03, 0.05, 0.20, 0.22, 0.45),
                  p_resp = c(0.05, 0.10, 0.50, 0.68, 0.70),
                  n_cohort = 10, cohort_size = 3, window = 1,
                  accrual_rate = 3, n_trials = 1000, seed = 123)
oc_bf <- do.call(sim_bf_boin_et, bf_design)
oc_bf
#> BF-BOIN-ET operating characteristics
#>   target DLT rate      : 0.3
#>   target response rate : 0.25
#>   trials               : 1000
#>   cohorts              : 10 of size 3
#>   patients per dose    : 12 at most with backfill
#>   lambda1 / lambda2    : 0.2365 / 0.3585
#>   eta1                 : 0.1968
#> 
#>                        DL1  DL2  DL3  DL4  DL5 Total / No OBD
#> True DLT rate (%)      3.0  5.0 20.0 22.0 45.0               
#> True response rate (%) 5.0 10.0 50.0 68.0 70.0               
#> OBD selected (%)       2.2  3.5 40.7 48.0  5.5            0.1
#> Patients treated       4.1  5.9 11.3  9.8  5.3           36.3
#> Patients backfilled    0.7  1.4  4.5  2.8  0.2            9.5
#> Patients with DLT      0.1  0.3  2.2  2.1  2.4            7.2
#> Patients with response 0.2  0.6  5.6  6.6  3.7           16.7
#> 
#> Trials stopped early: 0%
#> Average trial duration: 16.8

With suspend = 0.33 the next cohort may start while a third of the patients at the current dose are still assessed for DLT, which is the BF-BOIN-ET-A design of Takeda et al. (2025); the default, suspend = 0, is their BF-BOIN-ET-C design.

oc_bf_a <- do.call(sim_bf_boin_et, c(bf_design, list(suspend = 0.33)))
round(rbind(
  "BF-BOIN-ET-C" = c(oc_bf$sel_percent, patients = oc_bf$total_n_pts,
                     backfilled = oc_bf$total_n_bf,
                     months = oc_bf$duration),
  "BF-BOIN-ET-A" = c(oc_bf_a$sel_percent, patients = oc_bf_a$total_n_pts,
                     backfilled = oc_bf_a$total_n_bf,
                     months = oc_bf_a$duration)
), 1)
#>              DL1 DL2  DL3  DL4 DL5 patients backfilled months
#> BF-BOIN-ET-C 2.2 3.5 40.7 48.0 5.5     36.3        9.5   16.8
#> BF-BOIN-ET-A 3.2 3.5 40.8 45.5 6.2     33.6        6.1   13.3

The patients include the backfilled ones. The trials last 16.8 months on average under BF-BOIN-ET-C and 13.3 months under BF-BOIN-ET-A.

BOIN-ETC

When two drugs are given together, the doses form a matrix, with the L levels of drug A in the rows and the M levels of drug B in the columns. BOIN-ETC (Kakizume et al., 2024) divides the matrix into subtrials along which the DLT rate increases and runs the rules of BOIN-ET in each of them, from its lowest combination. A subtrial ends when the combination chosen for the next cohort already has n_earlystop patients (6 by default, n_stop of the article), and that combination is the candidate of the subtrial. The first subtrial goes up drug A at the lowest level of drug B and then along the highest level of drug A, A1B1, A2B1, ..., ALB1, ALB2, ..., ALBM. The three versions then differ (subtrials):

The names follow the figures, the tables and the code of the article; the text of its Section 2.2 describes BOIN-ETC2 and BOIN-ETC3 the other way round. A combination is excluded when the posterior probability that its DLT rate exceeds target is above cutoff_eli = 0.95, and with it the higher combinations of its subtrial; the subtrial ends when its lowest combination is excluded, and the trial ends when that combination is A1B1. In the code of the authors, the choice among the neighboring combinations when the decision of BOIN-ET is E/S/D moves one combination down when the combination below the current one is untreated; rule4 = "authors_code" applies this rule, and rule4 = "paper", the default, the rule of the text. Only etc1_start = "below" with rule4 = "authors_code" reproduces the allocation published for BOIN-ETC1.

At the end of the trial the DLT rates are made monotone along both drugs by bivariate isotonic regression, the MTD combination of every level of drug A bounds the candidates of that level, and the optimal dose combination (ODC) is the treated, not excluded candidate with the highest posterior mean of the utility of BOIN12, with the scores psi00 and psi11 (40 and 60 by default). boin_etc_select_obd() applies this selection to completed trials. When candidates tie, odc_tie = "lowest" (the default) selects the lowest one, and odc_tie = "all" counts every tied candidate, as the percentages of the article do.

Scenario 1 of the article has two levels of drug A, three of drug B, a target DLT rate of 0.30, a target response rate of 0.60 and at most 24 patients.

p_true_ab <- matrix(c(0.05, 0.10, 0.10, 0.30, 0.30, 0.50), nrow = 2)
p_resp_ab <- matrix(c(0.10, 0.25, 0.25, 0.60, 0.60, 0.65), nrow = 2)

oc_etc <- sim_boin_etc(target = 0.30, target_resp = 0.60, p_true = p_true_ab,
                       p_resp = p_resp_ab, n_cohort = 8, cohort_size = 3,
                       n_trials = 2000, seed = 123)
oc_etc
#> BOIN-ETC1 operating characteristics
#>   target DLT rate      : 0.3
#>   target response rate : 0.6
#>   dose levels          : 2 of drug A, 3 of drug B
#>   trials               : 2000
#>   cohorts              : 8 of size 3
#>   max sample size      : 24
#>   subtrial end (n_stop): 6
#>   lambda1/lambda2/eta1 : 0.14 / 0.35 / 0.48
#>   start of a row       : diagonal
#>   rule 4               : paper
#>   utility scores       : 100, 40, 60, 0; ties lowest
#> 
#>                    Item Drug A   B1   B2   B3
#>       True DLT rate (%)     A1  5.0 10.0 30.0
#>                             A2 10.0 30.0 50.0
#>  True response rate (%)     A1 10.0 25.0 60.0
#>                             A2 25.0 60.0 65.0
#>        OBD selected (%)     A1  3.4 11.3 31.3
#>                             A2 13.7 36.4  3.9
#>        Patients treated     A1  3.2  4.2  4.5
#>                             A2  4.3  4.9  1.3
#>       Patients with DLT     A1  0.2  0.4  1.3
#>                             A2  0.4  1.5  0.6
#>  Patients with response     A1  0.3  1.0  2.7
#>                             A2  1.1  3.0  0.8
#> 
#> No OBD selected                      : 0%
#> Trials stopped early                 : 0%
#> Average number of patients           : 22.3
#> Average number of subtrials          : 2
#> 
#> True OBD (highest true utility)      : A2B2, A1B3
#>   Selected as the OBD                : 67.8%
#>   Patients treated there             : 42.1%
#> Combinations above the target DLT    : 1 of 6
#>   Selected as the OBD                : 3.9%
#>   Patients treated there             : 5.7%

The true ODCs, the combinations with the highest utility among those with a DLT rate at most 0.30, are A2B2, A1B3. The three versions, and BOIN-ETC1 with the rules of the code of the authors, compare as follows, with tied ODCs counted as in the article:

etc_versions <- list(
  "BOIN-ETC1" = list(subtrials = "etc1"),
  "BOIN-ETC1, code" = list(subtrials = "etc1", etc1_start = "below",
                           rule4 = "authors_code"),
  "BOIN-ETC2" = list(subtrials = "etc2"),
  "BOIN-ETC3" = list(subtrials = "etc3")
)
etc_runs <- lapply(etc_versions, function(v) {
  do.call(sim_boin_etc,
          c(list(target = 0.30, target_resp = 0.60, p_true = p_true_ab,
                 p_resp = p_resp_ab, n_cohort = 8, cohort_size = 3,
                 n_trials = 2000, odc_tie = "all", seed = 123), v))
})
round(t(sapply(etc_runs, function(o) {
  c("ODC selected (%)" = o$pct_true_obd_selected,
    "Patients at ODC (%)" = o$pct_patients_true_obd,
    "Patients" = o$total_n_pts, "Subtrials" = o$mean_subtrials)
})), 1)
#>                 ODC selected (%) Patients at ODC (%) Patients Subtrials
#> BOIN-ETC1                   73.4                42.1     22.3         2
#> BOIN-ETC1, code             75.1                42.7     22.3         2
#> BOIN-ETC2                   73.4                42.1     22.3         2
#> BOIN-ETC3                   73.4                42.1     22.3         2

How the implementation is checked

The scripts in inst/reproduce/ and inst/validation/ compare the package with the articles and with the packages and the code of the authors, and write the tables of judgments in their results/ folders, which are summarized here. A simulated cell passes when it lies within four standard errors of the difference between the two simulations plus the rounding of the published value.

References

Takeda, K., Taguri, M. and Morita, S. (2018). BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes. Pharmaceutical Statistics, 17(4), 383-395.

Takeda, K., Morita, S. and Taguri, M. (2020). TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes. Pharmaceutical Statistics, 19(3), 335-349.

Takeda, K., Zhu, J. and Hirakawa, A. (2025). BF-BOIN-ET: A backfill Bayesian optimal interval design using efficacy and toxicity outcomes for dose optimization. Pharmaceutical Statistics, 24(2), e2470.

Yamaguchi, Y., Takeda, K. and Maruo, K. (2025). boinet: An R package for Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes. The R Journal, 17(2), 15-34.

Yamaguchi, Y., Takeda, K., Yoshida, S. and Maruo, K. (2024). Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study. Journal of Biopharmaceutical Statistics, 34(3), 379-393.

Kakizume, T., Takeda, K., Taguri, M. and Morita, S. (2024). BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations. Statistical Methods in Medical Research, 33(4), 716-727.

Lin, R. and Yin, G. (2017). STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Statistics in Medicine, 36(26), 4106-4120.